493 related articles for article (PubMed ID: 1941528)
41. Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience.
Delory T; Papot E; Rioux C; Charpentier C; Auge-Courtoi C; Michard F; Peytavin G; Descamps D; Matheron S; Yazdanpanah Y
J Med Virol; 2016 Jul; 88(7):1204-10. PubMed ID: 26636432
[TBL] [Abstract][Full Text] [Related]
42. Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials.
Staszewski S; Hill AM; Bartlett J; Eron JJ; Katlama C; Johnson J; Sawyer W; McDade H
AIDS; 1997 Mar; 11(4):477-83. PubMed ID: 9084795
[TBL] [Abstract][Full Text] [Related]
43. Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial.
Chung MH; Kiarie JN; Richardson BA; Lehman DA; Overbaugh J; Kinuthia J; Njiri F; John-Stewart GC
Antivir Ther; 2008; 13(6):799-807. PubMed ID: 18839781
[TBL] [Abstract][Full Text] [Related]
44. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group.
Revicki DA; Moyle G; Stellbrink HJ; Barker C
AIDS; 1999 May; 13(7):851-8. PubMed ID: 10357386
[TBL] [Abstract][Full Text] [Related]
45. Factors associated with changes in the use of antiretroviral therapy by a cohort of homosexual men infected with human immunodeficiency virus type 1.
Park LP; Graham NM; Jacobson LP; Murphy R; Besley D; Zucconi S; Muñoz A
Clin Infect Dis; 1995 Oct; 21(4):930-7. PubMed ID: 8645842
[TBL] [Abstract][Full Text] [Related]
46. Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity.
Barry M; Howe JL; Back DJ; Swart AM; Breckenridge AM; Weller IV; Beeching N; Nye F
Br J Clin Pharmacol; 1994 Jan; 37(1):7-12. PubMed ID: 8148221
[TBL] [Abstract][Full Text] [Related]
47. Size and duration of zidovudine benefit in 1003 HIV-infected patients: U.S. Army, Navy, and Air Force natural history data. Military Medical Consortium for Applied Retroviral Research.
Gardner LI; Harrison SH; Hendrix CW; Blatt SP; Wagner KF; Chung RC; Harris RW; Cohn DL; Burke DS; Mayers DL
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(4):345-53. PubMed ID: 9525436
[TBL] [Abstract][Full Text] [Related]
48. Saquinavir delays the emergence of zidovudine resistance in HIV-1 seropositive patients treated with combination therapy.
Andreoni M; Sarmati L; Nicastri E; Ventura L; Ercoli L; Parisi SG; Giannini G; Galluzzo C; Vella S
J Med Virol; 1998 Dec; 56(4):332-6. PubMed ID: 9829638
[TBL] [Abstract][Full Text] [Related]
49. Stavudine in zidovudine (ZDV)-experienced compared with ZDV-naive patients.
Gallant JE; Chaisson RE; Keruly JC; Moore RD
AIDS; 1999 Feb; 13(2):225-9. PubMed ID: 10202828
[TBL] [Abstract][Full Text] [Related]
50. A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression.
Saez-Llorens X; Castaño E; Rathore M; Church J; Deville J; Gaur A; Estripeaut D; White K; Arterburn S; Enejosa JV; Cheng AK; Chuck SL; Rhee MS
Pediatr Infect Dis J; 2015 Apr; 34(4):376-82. PubMed ID: 25760565
[TBL] [Abstract][Full Text] [Related]
51. Micronutrient status and human immunodeficiency virus (HIV) infection.
Bogden JD; Baker H; Frank O; Perez G; Kemp F; Bruening K; Louria D
Ann N Y Acad Sci; 1990; 587():189-95. PubMed ID: 2360760
[TBL] [Abstract][Full Text] [Related]
52. Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors.
Venturi G; Romano L; Catucci M; Riccio ML; De Milito A; Gonnelli A; Rubino M; Valensin PE; Zazzi M
Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):274-82. PubMed ID: 10385016
[TBL] [Abstract][Full Text] [Related]
53. Exposure to zidovudine adversely affects mitochondrial turnover in primary T cells.
Wallace ZR; Sanderson S; Simon AK; Dorrell L
Antiviral Res; 2016 Sep; 133():178-82. PubMed ID: 27496003
[TBL] [Abstract][Full Text] [Related]
54. HIV-1 infection in women is associated with severe nutritional deficiencies.
Baum MK; Shor-Posner G; Zhang G; Lai H; Quesada JA; Campa A; Jose-Burbano M; Fletcher MA; Sauberlich H; Page JB
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Dec; 16(4):272-8. PubMed ID: 9402074
[TBL] [Abstract][Full Text] [Related]
55. Serum immunoreactive erythropoietin levels and associated factors amongst HIV-infected children.
Allen UD; King SM; Gomez MP; Lapointe N; Forbes JC; Thorne A; Kirby MA; Bowker J; Raboud J; Singer J; Mukwaya G; Tobin J; Read SE
AIDS; 1998 Oct; 12(14):1785-91. PubMed ID: 9792379
[TBL] [Abstract][Full Text] [Related]
56. Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: Delta extended follow-up.
Delta Coordinating Committee
HIV Med; 2001 Jul; 2(3):181-8. PubMed ID: 11737399
[TBL] [Abstract][Full Text] [Related]
57. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients.
Kuritzkes DR; Quinn JB; Benoit SL; Shugarts DL; Griffin A; Bakhtiari M; Poticha D; Eron JJ; Fallon MA; Rubin M
AIDS; 1996 Aug; 10(9):975-81. PubMed ID: 8853730
[TBL] [Abstract][Full Text] [Related]
58. Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection.
Frissen PH; Weverling GJ; Endert E; Jansen J; Sauerwein HP; Lange JM
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):482-8. PubMed ID: 8757425
[TBL] [Abstract][Full Text] [Related]
59. Prophylactic ZDV therapy prevents early viremia and lymphocyte decline but not primary infection in feline immunodeficiency virus-inoculated cats.
Hayes KA; Lafrado LJ; Erickson JG; Marr JM; Mathes LE
J Acquir Immune Defic Syndr (1988); 1993 Feb; 6(2):127-34. PubMed ID: 8381867
[TBL] [Abstract][Full Text] [Related]
60. Prevalence of anaemia in HIV-infected children at the University of Abuja Teaching Hospital, Gwagwalada.
Okechukwu AA; Gambo D; Okechukwu IO
Niger J Med; 2010; 19(1):50-7. PubMed ID: 20232757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
